Robotic Stereotactic Body Radiation Therapy for the Adjuvant Treatment of Early-Stage Breast Cancer: Outcomes of a Large Single-Institution Study
Purpose: Advancements in breast radiation therapy offer innumerable benefits to patients and the health care system. Despite promising outcomes, clinicians remain hesitant about long-term side effects and disease control with accelerated partial breast radiation therapy (APBI). Herein, we review the...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-03-01
|
| Series: | Advances in Radiation Oncology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2452109422002019 |
| _version_ | 1811180691951452160 |
|---|---|
| author | Anna Jaysing, BA Jonathan W. Lischalk, MD Astrid Sanchez, MS Christopher Mendez, MA Phoebe May Amy Solan, MD Matthew Witten, PhD Zhanna Logman, MD Jonathan A. Haas, MD |
| author_facet | Anna Jaysing, BA Jonathan W. Lischalk, MD Astrid Sanchez, MS Christopher Mendez, MA Phoebe May Amy Solan, MD Matthew Witten, PhD Zhanna Logman, MD Jonathan A. Haas, MD |
| author_sort | Anna Jaysing, BA |
| collection | DOAJ |
| description | Purpose: Advancements in breast radiation therapy offer innumerable benefits to patients and the health care system. Despite promising outcomes, clinicians remain hesitant about long-term side effects and disease control with accelerated partial breast radiation therapy (APBI). Herein, we review the long-term outcomes of patients with early-stage breast cancer treated with adjuvant stereotactic partial breast irradiation (SAPBI). Methods and Materials: This retrospective study examined outcomes of patients who received diagnoses of early-stage breast cancer treated with adjuvant robotic SAPBI. All patients were eligible for standard ABPI and underwent lumpectomy, followed by fiducial placement in preparation for SAPBI. Using fiducial and respiratory tracking to maintain a precise dose distribution throughout the course of treatment, patients received 30 Gy in 5 fractions on consecutive days. Follow-up occurred at routine intervals to evaluate disease control, toxicity, and cosmesis. Toxicity and cosmesis were characterized using the Common Terminology Criteria for Adverse Events version 5.0 and Harvard Cosmesis Scale, respectively. Results: Patients (N = 50) were a median age of 68.5 years at the time of treatment. The median tumor size was 7.2 mm, 60% had an invasive cell type, and 90% were estrogen receptor positive, progesterone receptor positive, or both. Patients (n = 49) were followed for a median of 4.68 years for disease control and 1.25 years for cosmesis and toxicity. One patient experienced local recurrence, 1 patient experienced grade 3+ late toxicity, and 44 patients demonstrated excellent cosmesis. Conclusions: To our knowledge, this is the largest retrospective analysis with the longest follow-up time for disease control among patients with early breast cancer treated with robotic SAPBI. With follow-up time for cosmesis and toxicity comparable to that of previous studies, results of the present cohort advance our understanding of the excellent disease control, excellent cosmesis, and limited toxicity that can be achieved by treating select patients with early-stage breast cancer with robotic SAPBI. |
| first_indexed | 2024-04-11T09:07:34Z |
| format | Article |
| id | doaj.art-bfa5bf3b6d564853bc4b93c7f2738705 |
| institution | Directory Open Access Journal |
| issn | 2452-1094 |
| language | English |
| last_indexed | 2024-04-11T09:07:34Z |
| publishDate | 2023-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Advances in Radiation Oncology |
| spelling | doaj.art-bfa5bf3b6d564853bc4b93c7f27387052022-12-22T04:32:35ZengElsevierAdvances in Radiation Oncology2452-10942023-03-0182101095Robotic Stereotactic Body Radiation Therapy for the Adjuvant Treatment of Early-Stage Breast Cancer: Outcomes of a Large Single-Institution StudyAnna Jaysing, BA0Jonathan W. Lischalk, MD1Astrid Sanchez, MS2Christopher Mendez, MA3Phoebe May4Amy Solan, MD5Matthew Witten, PhD6Zhanna Logman, MD7Jonathan A. Haas, MD8Department of Radiation Oncology, New York University Long Island School of Medicine, New York, New YorkDepartment of Radiation Oncology, Perlmutter Cancer Center at New York University Langone Hospital – Long Island, Mineola, New York; Corresponding author: Jonathan W. Lischalk, MDDepartment of Radiation Oncology, Perlmutter Cancer Center at New York University Langone Hospital – Long Island, Mineola, New YorkDepartment of Radiation Oncology, Perlmutter Cancer Center at New York University Langone Hospital – Long Island, Mineola, New YorkDepartment of Radiation Oncology, Perlmutter Cancer Center at New York University Langone Hospital – Long Island, Mineola, New YorkDepartment of Radiation Oncology, Perlmutter Cancer Center at New York University Langone Hospital – Long Island, Mineola, New YorkDepartment of Radiation Oncology, Perlmutter Cancer Center at New York University Langone Hospital – Long Island, Mineola, New YorkDepartment of Surgery, New York University Langone Hospital – Long Island, Mineola, New YorkDepartment of Radiation Oncology, Perlmutter Cancer Center at New York University Langone Hospital – Long Island, Mineola, New YorkPurpose: Advancements in breast radiation therapy offer innumerable benefits to patients and the health care system. Despite promising outcomes, clinicians remain hesitant about long-term side effects and disease control with accelerated partial breast radiation therapy (APBI). Herein, we review the long-term outcomes of patients with early-stage breast cancer treated with adjuvant stereotactic partial breast irradiation (SAPBI). Methods and Materials: This retrospective study examined outcomes of patients who received diagnoses of early-stage breast cancer treated with adjuvant robotic SAPBI. All patients were eligible for standard ABPI and underwent lumpectomy, followed by fiducial placement in preparation for SAPBI. Using fiducial and respiratory tracking to maintain a precise dose distribution throughout the course of treatment, patients received 30 Gy in 5 fractions on consecutive days. Follow-up occurred at routine intervals to evaluate disease control, toxicity, and cosmesis. Toxicity and cosmesis were characterized using the Common Terminology Criteria for Adverse Events version 5.0 and Harvard Cosmesis Scale, respectively. Results: Patients (N = 50) were a median age of 68.5 years at the time of treatment. The median tumor size was 7.2 mm, 60% had an invasive cell type, and 90% were estrogen receptor positive, progesterone receptor positive, or both. Patients (n = 49) were followed for a median of 4.68 years for disease control and 1.25 years for cosmesis and toxicity. One patient experienced local recurrence, 1 patient experienced grade 3+ late toxicity, and 44 patients demonstrated excellent cosmesis. Conclusions: To our knowledge, this is the largest retrospective analysis with the longest follow-up time for disease control among patients with early breast cancer treated with robotic SAPBI. With follow-up time for cosmesis and toxicity comparable to that of previous studies, results of the present cohort advance our understanding of the excellent disease control, excellent cosmesis, and limited toxicity that can be achieved by treating select patients with early-stage breast cancer with robotic SAPBI.http://www.sciencedirect.com/science/article/pii/S2452109422002019 |
| spellingShingle | Anna Jaysing, BA Jonathan W. Lischalk, MD Astrid Sanchez, MS Christopher Mendez, MA Phoebe May Amy Solan, MD Matthew Witten, PhD Zhanna Logman, MD Jonathan A. Haas, MD Robotic Stereotactic Body Radiation Therapy for the Adjuvant Treatment of Early-Stage Breast Cancer: Outcomes of a Large Single-Institution Study Advances in Radiation Oncology |
| title | Robotic Stereotactic Body Radiation Therapy for the Adjuvant Treatment of Early-Stage Breast Cancer: Outcomes of a Large Single-Institution Study |
| title_full | Robotic Stereotactic Body Radiation Therapy for the Adjuvant Treatment of Early-Stage Breast Cancer: Outcomes of a Large Single-Institution Study |
| title_fullStr | Robotic Stereotactic Body Radiation Therapy for the Adjuvant Treatment of Early-Stage Breast Cancer: Outcomes of a Large Single-Institution Study |
| title_full_unstemmed | Robotic Stereotactic Body Radiation Therapy for the Adjuvant Treatment of Early-Stage Breast Cancer: Outcomes of a Large Single-Institution Study |
| title_short | Robotic Stereotactic Body Radiation Therapy for the Adjuvant Treatment of Early-Stage Breast Cancer: Outcomes of a Large Single-Institution Study |
| title_sort | robotic stereotactic body radiation therapy for the adjuvant treatment of early stage breast cancer outcomes of a large single institution study |
| url | http://www.sciencedirect.com/science/article/pii/S2452109422002019 |
| work_keys_str_mv | AT annajaysingba roboticstereotacticbodyradiationtherapyfortheadjuvanttreatmentofearlystagebreastcanceroutcomesofalargesingleinstitutionstudy AT jonathanwlischalkmd roboticstereotacticbodyradiationtherapyfortheadjuvanttreatmentofearlystagebreastcanceroutcomesofalargesingleinstitutionstudy AT astridsanchezms roboticstereotacticbodyradiationtherapyfortheadjuvanttreatmentofearlystagebreastcanceroutcomesofalargesingleinstitutionstudy AT christophermendezma roboticstereotacticbodyradiationtherapyfortheadjuvanttreatmentofearlystagebreastcanceroutcomesofalargesingleinstitutionstudy AT phoebemay roboticstereotacticbodyradiationtherapyfortheadjuvanttreatmentofearlystagebreastcanceroutcomesofalargesingleinstitutionstudy AT amysolanmd roboticstereotacticbodyradiationtherapyfortheadjuvanttreatmentofearlystagebreastcanceroutcomesofalargesingleinstitutionstudy AT matthewwittenphd roboticstereotacticbodyradiationtherapyfortheadjuvanttreatmentofearlystagebreastcanceroutcomesofalargesingleinstitutionstudy AT zhannalogmanmd roboticstereotacticbodyradiationtherapyfortheadjuvanttreatmentofearlystagebreastcanceroutcomesofalargesingleinstitutionstudy AT jonathanahaasmd roboticstereotacticbodyradiationtherapyfortheadjuvanttreatmentofearlystagebreastcanceroutcomesofalargesingleinstitutionstudy |